BD2

Feinstein Institutes Awarded $6.1M to Fund Bipolar Disorder Patient and Research Hub

Retrieved on: 
Thursday, October 19, 2023
Mental Health, Health, Biometrics, Clinical Trials, Research, Science, Biotechnology, Knowledge, Patient, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Medical research, Feinstein, Feinstein Institutes for Medical Research, Transcranial magnetic stimulation, Johns Hopkins University, Zucker Hillside Hospital, Hofstra University, Psychiatry, Bipolar disorder, Multimedia, Donald, Clinical trial, Schizophrenia, Institutional review board, Behavioural sciences, Credit, University, Magnetic resonance imaging, University of California, Los Angeles, BD2, University of Michigan, Hospital, BSN, Mayo Clinic, Pharmaceutical industry, MD, Brigham, Wellcome

Approximately 2.3 million Americans live with bipolar disorder who are impacted by dramatic shifts in mood, energy and activity levels.

Key Points: 
  • Approximately 2.3 million Americans live with bipolar disorder who are impacted by dramatic shifts in mood, energy and activity levels.
  • Through a national research grant and innovative networking system aimed to connect patients to care, it might become easier for people with bipolar disorder to find new treatments and clinical trials.
  • (Credit: Feinstein Institutes)
    Researchers at The Feinstein Institutes for Medical Research received a $6.1 million grant from Breakthrough Discoveries for Thriving with Bipolar Disorders Foundation (BD2) to serve as a hub of six other sites across the country.
  • “Although bipolar disorder impacts millions of Americans every year, it is under-researched,” said Kevin J. Tracey, MD , president and CEO of the Feinstein Institutes and Karches Family Distinguished Chair in Medical Research.

VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

Retrieved on: 
Monday, May 1, 2023
Research, H4, BET, H3, Attention deficit hyperactivity disorder predominantly inattentive, BD2, BD1, Therapy, Thrombocytopenia, Gene, Safety, Tay, Pharmaceutical industry, IND

BRIDGEWATER, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the selection of a development candidate for its oral BD2-selective bromodomain and extra-terminal (“BET”) inhibitor program, VYN202, for the treatment of immuno-inflammatory conditions. The lead candidate was selected by VYNE from a library of BD2-selective BET inhibitors that VYNE exclusively licensed from Tay Therapeutics following the receipt of a robust package of preclinical data, including encouraging results from well-validated animal models in various autoimmune disorders. VYNE also obtained rights to several other BD2-selective BET inhibitor compounds with attractive molecular profiles that the Company may develop, at its discretion, in the future.

Key Points: 
  • BRIDGEWATER, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the selection of a development candidate for its oral BD2-selective bromodomain and extra-terminal (“BET”) inhibitor program, VYN202, for the treatment of immuno-inflammatory conditions.
  • The lead candidate was selected by VYNE from a library of BD2-selective BET inhibitors that VYNE exclusively licensed from Tay Therapeutics following the receipt of a robust package of preclinical data, including encouraging results from well-validated animal models in various autoimmune disorders.
  • VYNE also obtained rights to several other BD2-selective BET inhibitor compounds with attractive molecular profiles that the Company may develop, at its discretion, in the future.
  • As epigenetic readers, BET proteins are super-enhancers of gene transcription that drive the hyperactive production of many pro-inflammatory proteins that characterize autoimmune and autoinflammatory diseases.

VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 9, 2023
School of Life Sciences (University of Dundee), University, BD2, IND, Letter, BD1, Therapy, Patient, FDA, Vitiligo, AD, Disease, Patent, Inflammation, Atopic dermatitis, BET, Pharmaceutical industry

BRIDGEWATER, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the fourth quarter and year ended December 31, 2022 and provided a business update.

Key Points: 
  • “With only one FDA-approved therapy currently available for this large patient population, vitiligo remains a significant unmet medical need.
  • Based on these preliminary results, the Company has selected three doses for testing in the Phase 1b portion of the trial.
  • The patent, exclusively licensed to Tay Therapeutics Ltd. ("Tay") and sublicensed to VYNE, will expire in April 2040.
  • In February 2023, VYNE and its license partner, Tay, extended the exclusive option agreement for VYN202 to April 30, 2023.

InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions

Retrieved on: 
Friday, September 30, 2022
Human body, VP, Safety, Infection, TSX, COVID-19, Risk, FDA, Virus, Feedback, Conditional sentence, Suggestion, Senior, News, Industry, Apabetalone, End organ damage, BD2, PCC, Patient, Cell, Vaccination, CDC, BET, Post, US Foods, GLOBE, Awareness, HIV disease progression rates, Drug, Pharmaceutical industry

VANCOUVER, British Columbia, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (TSX:RVX) (OTCPink:RVXCF), a world leader in epigenetics, or gene regulation, announced that apabetalones future development related to COVID-19, will focus on the prevention and treatment of Post COVID-19 Conditions.

Key Points: 
  • VANCOUVER, British Columbia, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (TSX:RVX) (OTCPink:RVXCF), a world leader in epigenetics, or gene regulation, announced that apabetalones future development related to COVID-19, will focus on the prevention and treatment of Post COVID-19 Conditions.
  • If these links are not enabled, please visit www.InvestmentPitch.com and enter Resverlogix in the search box.
  • A recent estimate from the CDC suggests that as many as one-in-three US adults may experience long-COVID after contracting COVID-19.
  • Resverlogix has paid a fee not exceeding $2,000 in cash to have its current news release produced in video format.

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

Retrieved on: 
Wednesday, September 28, 2022
Human body, Safety, Infection, TSX, COVID-19, Risk, FDA, Apabetalone, Food, Virus, Feedback, Conditional sentence, Legislation, Nature, Intention, Company, Senior, News, Breakthrough therapy, Industry, End organ damage, BD2, PCC, Patient, Cell, Vaccination, CDC, Centers for Disease Control and Prevention, Cardiovascular disease, BET, Post, Use-centered design, US Food Sovereignty Alliance, GLOBE, SEDAR, Drug, Disease, Pharmaceutical industry, Vaccine, Medical device

There are currently few available treatment options for this group of people, and we feel that apabetalone has great potential to help them.

Key Points: 
  • There are currently few available treatment options for this group of people, and we feel that apabetalone has great potential to help them.
  • The investigational treatment could potentially reduce the severity and duration of post COVID-19 conditions.
  • Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes.
  • The Companys clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease and associated comorbidities, and COVID-19.

Global Platform Launches to Transform Bipolar Disorder Research and Care

Retrieved on: 
Monday, September 12, 2022
Science, Milken Institute, Health, Bipolar disorder, Parkinson's disease, Biomedical Research, Hospital, ASAP, Knowledge, North East Local Health Integration Network, Google, Cognition, Bangladesh Technical Education Board, Massachusetts General Hospital, BD2, Foundation, Genotype, Mental health, Investment, Neurological disorder, List of acquisitions by Cisco Systems, CEO, Genetics, Leadership, Doctor of Philosophy, Diagnosis, Method, Thought disorder, Research, Overalls, David Baszucki, Multimedia, Environmental health, Milken, Disease, Pharmaceutical industry, Management, Roblox

WASHINGTON, Sept. 12, 2022 /PRNewswire/ -- Today, three family philanthropies joined with the Milken Institute to commit $150 million to launch BD2: Breakthrough Discoveries for thriving with Bipolar Disorder.

Key Points: 
  • While funding for mental health has increased overall, federal funding for research related exclusively to bipolar disorder has decreased by 50% over the past 10 years .
  • Kent Dauten and his wife, Liz, have supported bipolar disorder research extensively after two of their four children were diagnosed as teenagers.
  • "Together, we will accelerate discoveries for bipolar disorder and demonstrate that our approach to collaborative funding and integrated research is a new model for biomedical research."
  • The study design and infrastructure prioritize rapid implementation of research findings to improve treatment for all those living with bipolar disorder."

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

Retrieved on: 
Monday, August 22, 2022
Cardiovascular disease, Cardiology, COVID-19, Conditional sentence, Non-alcoholic fatty liver disease, Safety, Cell, Legislation, Breakthrough therapy, Risk, HHF, Moderate, Disease, US Foods, FS, Virus, Food, BD2, BET, TSX, GLOBE, Intention, Â, Cirrhosis, Company, FDA, Bromodomain, American Journal, News, Type 2 diabetes, MACE, SEDAR, Industry, Human body, European Journal of Preventive Cardiology, Acute coronary syndrome, End organ damage, Nature, Pharmaceutical industry, Dietary supplement, Medical device, Apabetalone, Patient

The article presents a post-hoc analysis of BETonMACE data, which demonstrates apabetalone treatment improves cardiac outcomes and liver fibrosis scores in patients with moderate-to-high likelihood of advanced liver fibrosis.

Key Points: 
  • The article presents a post-hoc analysis of BETonMACE data, which demonstrates apabetalone treatment improves cardiac outcomes and liver fibrosis scores in patients with moderate-to-high likelihood of advanced liver fibrosis.
  • These promising findings make the case for a larger study of non-alcoholic fatty liver disease patients to better understand the scope of apabetalones benefit.
  • It is a BD2 (bromodomain) selective BET (bromodomain andextra-terminal) inhibitorthat works in preventing and treating disease progression byregulating the expression of disease-causing genes.
  • Data from BETonMACE showed apabetalone can potentially prevent major adverse cardiac events among high-risk cardiovascular disease patients who also have type 2 diabetes mellitus.

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

Retrieved on: 
Wednesday, June 8, 2022
Conditional sentence, BD2, Apabetalone, Chromatin, Company, Research, Cell, US Foods, Cell death, Food, Legislation, BRD4, Nature, News, Beti, Disease, Inflammation, Senior, End organ damage, Breakthrough therapy, Fabry disease, BET, Cardiovascular disease, FDA, GLOBE, Patient, TAD, Biomedicine & Pharmacotherapy, COVID-19, Risk, Research and development, TSX, Industry, Virus, Human body, Pharmacology, Intention, Safety, SEDAR, Online gambling, Pharmaceutical industry, Medical device, Fabry

The article uncovers a clear mechanism for the improved safety, and reduced off-target effects, seen with BD2-selective BET inhibitors in comparison with non-selective BET inhibitors.

Key Points: 
  • The article uncovers a clear mechanism for the improved safety, and reduced off-target effects, seen with BD2-selective BET inhibitors in comparison with non-selective BET inhibitors.
  • BD2-selective inhibitors, such as apabetalone, can inhibit the expression of disease-causing genes without disrupting the fundamental functions of cells.
  • The article details the beneficial impacts of apabetalone treatment on inflammatory pathways in immune cells from Fabry disease patients.
  • These findings suggest that apabetalone is a promising therapeutic candidate for the rare disorder.

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

Retrieved on: 
Monday, May 9, 2022
Efficacy, Safety, TSX, Human body, Solution, High Risk, Breakthrough therapy, Risk, SEDAR, Twitter, Company, Heart failure, Patient, Infection, Partnership, Clinical trial, Potential, FDA, End organ damage, Industry, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hospital, Conditional sentence, LinkedIn, Intention, Disease, COVID-19, News, Research, Type, Albert Einstein College of Medicine, Stroke, Cell, Virus, University, Montefiore Medical Center, CORAL, BD2, GLOBE, Food, Cardiovascular disease, Legislation, BET, Organization, US Foods, History, Apabetalone, Health information management, Pharmaceutical industry, Medical device, Nature, Medicine

Resverlogix will conclude its Phase 2 trial in hospitalized COVID-19 patients early, thus focusing its resources on the advanced Phase 3 program.

Key Points: 
  • Resverlogix will conclude its Phase 2 trial in hospitalized COVID-19 patients early, thus focusing its resources on the advanced Phase 3 program.
  • Were pleased to support this important evolution of apabetalone and Resverlogix in its Phase 3 CORAL study, said Kevin McDermott, Resverlogix Chief Commercial Officer, EVERSANA.
  • The EVERSANA COMPLETE Commercialization model is built to support customer needs by offering flexibility to quickly adapt development and launch strategies to meet market demands.
  • Study site selection is currently underway, with sites expected in the United States, Canada, and the Middle East.

Resverlogix Announces One-Year Extension of Debenture

Retrieved on: 
Tuesday, April 19, 2022
News, CEO, Conditional sentence, BET, COVID-19, US Foods, Risk, Legislation, Apabetalone, Research, Intention, Food, BD2, GLOBE, Patient, Cell, End organ damage, Standard of care, Human body, Company, Breakthrough therapy, TSX, University, Partnership, FDA, Disease, Industry, SEDAR, Virus, Cardiovascular disease, Pharmaceutical industry, Medical device, Nature

CALGARY, Alberta, April 19, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the Company) (TSX:RVX) announced today that it has closed a one-year extension of Companys US$6.0 million 10% secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink"), and payment of accrued interest thereon, extending the maturity date to May 13, 2023.

Key Points: 
  • CALGARY, Alberta, April 19, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the Company) (TSX:RVX) announced today that it has closed a one-year extension of Companys US$6.0 million 10% secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink"), and payment of accrued interest thereon, extending the maturity date to May 13, 2023.
  • It is a BD2 (bromodomain) selective BET (bromodomain andextra-terminal) inhibitorthat works in preventing and treating disease progression byregulating the expression of disease-causing genes.
  • Following a publication in Nature , authored by a consortium of top Universities and Research Institutions, on March 23, 2020, Resverlogix launched a COVID-19 program, conducting research internally and enlisting world-renowned collaborators.
  • Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes.